Drug
Hypromellose Derivatives clinical trials
Also written Hydroxypropylmethylcellulose.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 6
Allergan (3) · University of California, San Francisco (1) · The University of Hong Kong (1) · Augusta University (1) · University of Campinas, Brazil (1) · University of Sao Paulo (1) · Mahidol University (1)
Often tested with
Tested in the same studies.
Timolol (3) · Travoprost (3) · Bimatoprost (2) · Hyaluronic Acid (2) · Chlorhexidine (1) · Povidone-Iodine (1) · Prednisolone phosphate (1) · Prednisolone (1)
Studies
Open first, then newest update. How each study uses Hypromellose Derivatives is read from its arms, and is right about nine times in ten.
Testing it · 9
- Parasitic Ulcer Treatment Trial PilotCompletedPhase 2University of California, San FranciscoNCT03484507Written as Hydroxypropyl Methylcellulose
- Interval Intraocular Pressure in Intravitreal Injection StudyCompletedNot applicableThe University of Hong KongNCT04868175Written as Hypromellose
- GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK PatientsCompletedPhase 4Augusta UniversityNCT00598689Written as 0.3% hypromellose
- Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionCompletedPhase 4AllerganNCT02097719Written as hypromellose 0.3%
- An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionCompletedPhase 4AllerganNCT01881126Written as hypromellose 0.3%
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionCompletedPhase 4AllerganNCT01525173Written as 0.2% hypromellose lubricant eye drops
- The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic PatientsCompletedPhase 4University of Campinas, BrazilNCT01280110Written as Hydroxypropylmethylcellulose
- Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%CompletedPhase 4University of Sao PauloNCT01387620Written as Hyaluronic Acid and hydroxypropylmethylcellulose
- Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in GlaucomaStatus unknownNot applicableMahidol UniversityNCT01284439Written as hydroxypropylmethylcellulose
Given in every arm · 2 — Hypromellose Derivatives is usual care beside what is tested
- Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry EyeCompletedPhase 2Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.NCT03676335Written as Hypromellose Eye Drops
- Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL).Status unknownPhase 1/2Oslo University HospitalNCT02883478Written as riboflavin with hydroxypropyl methylcellulose
As the comparator · 1 — what is tested is compared with Hypromellose Derivatives
Codes
What other systems call Hypromellose Derivatives · ClinicalTrials.gg INT008988
- MeSH (NLM) D065347Hypromellose DerivativesOne source NLM
- UNII (FDA) 3NXW29V3WOHYPROMELLOSE, UNSPECIFIEDConfirmed FDA, NLM
- RxNorm 27334One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D065347 | Hypromellose Derivatives | One source NLM |
| UNII (FDA) | 3NXW29V3WO | HYPROMELLOSE, UNSPECIFIED | Confirmed FDA, NLM |
| RxNorm | 27334 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.